Mefoxin (Cefoxitin Sodium)

Cefoxitin works by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final stages of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its activity covers many Gram‑positive and Gram‑negative organisms, making it a broad‑spectrum agent.

The dosage of Mefoxin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Healthcare providers calculate the appropriate intravenous dose and infusion rate for each individual case.

Safety data for cefoxitin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case carefully and discuss potential risks with the patient.

To order Mefoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Mefoxin (cefoxitin) is a second‑generation cephalosporin offering broader activity against anaerobic bacteria compared with many first‑generation agents. It provides reliable coverage for mixed aerobic‑anaerobic infections, especially intra‑abdominal and gynecologic infections, while maintaining a safety profile similar to other cephalosporins.

Mefoxin should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the product if it has been exposed to temperatures outside the recommended range.

Mefoxin is administered intravenously by a qualified healthcare professional. The solution is typically diluted in an appropriate compatible fluid and infused over a specified period, as directed by the prescriber. Administration techniques follow standard aseptic and infusion‑rate guidelines.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hemolytic anemia, neutropenia, and renal impairment. Patients should be monitored for signs of hypersensitivity, gastrointestinal disturbances, and changes in blood counts or kidney function during therapy.

Mefoxin is contraindicated in individuals with a known hypersensitivity to cefoxitin, other cephalosporins, or any penicillin‑derived antibiotics. Caution is also advised for patients with a history of severe allergic reactions to beta‑lactam antibiotics. Clinicians should assess each patient’s medical history before prescribing.